|1.||Old, Lloyd J: 20 articles (10/2015 - 07/2002)|
|2.||Kawakami, Yutaka: 12 articles (01/2014 - 06/2003)|
|3.||Disis, Mary L: 11 articles (01/2015 - 08/2003)|
|4.||Rosenberg, Steven A: 11 articles (02/2014 - 07/2002)|
|5.||Ritter, Gerd: 9 articles (10/2015 - 07/2002)|
|6.||Finn, Olivera J: 9 articles (08/2014 - 01/2004)|
|7.||Chen, Yao-Tseng: 9 articles (05/2014 - 07/2002)|
|8.||Gnjatic, Sacha: 9 articles (04/2014 - 07/2007)|
|9.||Andersen, Mads Hald: 9 articles (01/2012 - 12/2003)|
|10.||Schlom, Jeffrey: 9 articles (09/2011 - 01/2002)|
03/01/2007 - "This is the first report to show that most established tumors were successfully eradicated by collaboration of potent antitumor immunity and anti-angiogenic effects by vaccination with tumor antigens and helper-activating analogs. "
06/28/2002 - "A paradox may emerge when vaccination is attempted in these two groups of subjects, with the second group being more prone to develop an effective immune response if the vaccine is potent enough to activate naive T cells, while the first has probably already eliminated most of the tumor antigens potentially recognizable by the host T cells owing to the previous selection made by the immune response developed early during tumor growth. "
01/01/2011 - "This immunization approach could be adapted to elicit potent immunity against multiple tumor antigens, resulting in a broader immune response that was more effective in targeting human tumor cells. "
01/01/2006 - "The work of my laboratory aims to provide evidence in animal models as well as in cancer patients that immune system can control cancer growth and that this important function can be improved through vaccination with well-defined tumor antigens."
01/01/1982 - "In contrast, when a sufficient amount of tumor antigens (higher dose of tumor cells injected and CY injection delayed) elicited an anti-YAS immune response that was not suppressed by early injection of CY (CY administered 5 days after the tumor) effective eradication of tumor cells and anti-YAS resistance in cured animals were observed."
|2.||Melanoma (Melanoma, Malignant)
09/01/1998 - "PMCV induces both humoral and cell-mediated immune responses to melanoma-associated tumor antigens, the type and strength of which appear to be directly related to its therapeutic efficacy."
10/01/2010 - "Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial."
01/01/2004 - "Early clinical trials, mostly in the setting of melanoma, have shown that dendritic cells (DCs) expressing tumor antigens induce some immune responses and some clinical responses. "
12/01/1996 - "A large majority of these studies focused on melanoma-associated tumor antigens because of the collective evidence that the immune system can influence the pathogenesis of melanoma, and because of the well-documented, although limited, success of immunotherapeutic modalities in melanoma patients. "
05/15/1990 - "This study attempts to characterize human melanoma-associated tumor antigens that are recognized by autologous T-lymphocyte clones. "
04/01/1987 - "In cells bearing the plasmid, we detected a low level of material that cross-reacts with antibody to polyoma tumor antigens, suggesting that the plasmids replicate and are maintained in the cells by a mechanism different from that functioning during propagation following infection of papovaviruses."
04/15/1986 - "Role of the adenovirus early region 1B tumor antigens in transformation and lytic infection."
09/01/1983 - "The implications of these findings for the roles of the Ad5 tumor antigens in lytic infection and transformation are discussed."
09/01/1983 - "The intracellular localization of tumor antigens of human adenovirus type 5 (Ad5) during lytic infection of KB cells has been studied. "
02/01/2012 - "Thus, immunotherapy based on the blockade of PD-1/PD-L1 interaction does not only result in breakdown of effector T-cell tolerance to tumor antigens, but in addition also represents a promising therapeutic strategy for reactivation of virus-specific effector T cells to exert pathogen eradication in chronic viral infections. "
01/01/2014 - "Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells."
07/17/2008 - "In this study we applied a serological proteomics-based approach (SERPA) to identify tumor antigens that commonly induce a humoral immune response in patients with infiltrating ductal breast carcinomas. "
07/01/2005 - "This study was to screen and identify tumor antigens of ovarian carcinoma by Western blot, immunoprecipitation, and mass spectrometry, and to establish a new methodological entity. "
04/01/2001 - "Identification of the phenotype and requirements for effector function of T lymphocytes sensitized to tumor antigens has implications for clinical trials of adoptive immunotherapy for head and neck carcinoma using a similar approach."
06/01/2015 - "Here, we show that antibody-mediated TGFβ neutralization during radiation therapy effectively generates CD8(+) T-cell responses to multiple endogenous tumor antigens in poorly immunogenic mouse carcinomas. "
|5.||Breast Neoplasms (Breast Cancer)
06/01/2013 - "The study protocol involved one transfusion of TCs which were reactivated in vitro with autologous dendritic cells pulsed with lysates of MCF-7 breast cancer cells as source of tumor antigens. "
03/01/2007 - "The goal of this study was to investigate whether the tumor antigens expressed on breast cancer cells may be preserved after HIFU treatment, and to explore the potential mechanisms regarding the enhanced antitumor response. "
01/01/2006 - "A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage display."
02/01/2015 - "Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer."
06/01/2013 - "Proteomics technologies are well suited for harnessing the immune response to tumor antigens for diagnostic applications as in the case of breast cancer. "
|8.||DNA (Deoxyribonucleic Acid)
|9.||RNA (Ribonucleic Acid)
|3.||Transplantation (Transplant Recipients)
|4.||Drug Therapy (Chemotherapy)